AIM: To evaluate the risk associated with variants of the UNC5C gene recently suspected to predispose to familial colorectal cancer (CRC). METHODS: We screened patients with familial CRC forms as well as patients with sporadic CRCs. In a first time, we analyzed exon 11 of the UNC5C gene in 120 unrelated patients with suspected hereditary CRC, 58 patients with suspected Lynch-associated cancer or polyposis, and 132 index cases of Lynch syndrome families with a characterized mutation in a DNA mismatch repair (MMR). Next, 1023 patients with sporadic CRC and 1121 healthy individuals were screened for the variants identified in patients with familial cancer. RESULTS: Of 120 patients with familial CRC of unknown etiology, one carried the previously reported mis-sense mutation p.Arg603Cys (R603C) and another exhibited the unreported variant of unknown significance p.Thr617Ile (T617I). The p.Ala628Lys (A628K) mutation previously described as the main UNC5C risk variant for familial CRC was not detected in any cases of familial CRC of unknown etiology, but was present in a patient with familial gastric cancer and in two Lynch syndrome patients in co-occurrence with MMR mutations. A statistically non-significant increase in cancer risk was identified in familial CRC and/or other Lynch-associated cancers (1/178 patients vs 2/1121 healthy controls, OR = 3.2, 95%CI: 0.29-35.05, P = 0.348) and in sporadic CRCs (4/1023 patients vs 2/1121 healthy controls, OR = 2.2, 95%CI: 0.40-12.02, P = 0.364). CONCLUSION: We confirm that UNC5C mutations are very rare in familial and sporadic CRCs, but further investigations are needed to justify routine UNC5C testing for diagnostic purposes.
AIM: To evaluate the risk associated with variants of the UNC5C gene recently suspected to predispose to familial colorectal cancer (CRC). METHODS: We screened patients with familial CRC forms as well as patients with sporadic CRCs. In a first time, we analyzed exon 11 of the UNC5C gene in 120 unrelated patients with suspected hereditary CRC, 58 patients with suspected Lynch-associated cancer or polyposis, and 132 index cases of Lynch syndrome families with a characterized mutation in a DNA mismatch repair (MMR). Next, 1023 patients with sporadic CRC and 1121 healthy individuals were screened for the variants identified in patients with familial cancer. RESULTS: Of 120 patients with familial CRC of unknown etiology, one carried the previously reported mis-sense mutation p.Arg603Cys (R603C) and another exhibited the unreported variant of unknown significance p.Thr617Ile (T617I). The p.Ala628Lys (A628K) mutation previously described as the main UNC5C risk variant for familial CRC was not detected in any cases of familial CRC of unknown etiology, but was present in a patient with familial gastric cancer and in two Lynch syndromepatients in co-occurrence with MMR mutations. A statistically non-significant increase in cancer risk was identified in familial CRC and/or other Lynch-associated cancers (1/178 patients vs 2/1121 healthy controls, OR = 3.2, 95%CI: 0.29-35.05, P = 0.348) and in sporadic CRCs (4/1023 patients vs 2/1121 healthy controls, OR = 2.2, 95%CI: 0.40-12.02, P = 0.364). CONCLUSION: We confirm that UNC5C mutations are very rare in familial and sporadic CRCs, but further investigations are needed to justify routine UNC5C testing for diagnostic purposes.
Authors: Carolyn M Hutter; Jenny Chang-Claude; Martha L Slattery; Bethann M Pflugeisen; Yi Lin; David Duggan; Hongmei Nan; Mathieu Lemire; Jagadish Rangrej; Jane C Figueiredo; Shuo Jiao; Tabitha A Harrison; Yan Liu; Lin S Chen; Deanna L Stelling; Greg S Warnick; Michael Hoffmeister; Sébastien Küry; Charles S Fuchs; Edward Giovannucci; Aditi Hazra; Peter Kraft; David J Hunter; Steven Gallinger; Brent W Zanke; Hermann Brenner; Bernd Frank; Jing Ma; Cornelia M Ulrich; Emily White; Polly A Newcomb; Charles Kooperberg; Andrea Z LaCroix; Ross L Prentice; Rebecca D Jackson; Robert E Schoen; Stephen J Chanock; Sonja I Berndt; Richard B Hayes; Bette J Caan; John D Potter; Li Hsu; Stéphane Bézieau; Andrew T Chan; Thomas J Hudson; Ulrike Peters Journal: Cancer Res Date: 2012-02-24 Impact factor: 12.701
Authors: Anna Abulí; Xavier Bessa; Juan Ramón González; Clara Ruiz-Ponte; Alejandro Cáceres; Jenifer Muñoz; Victoria Gonzalo; Francesc Balaguer; Ceres Fernández-Rozadilla; Dolors González; Luisa de Castro; Juan Clofent; Luís Bujanda; Joaquín Cubiella; Josep M A Reñé; Juan Diego Morillas; Angel Lanas; Joaquim Rigau; Ana M A García; Mercedes Latorre; Joan Saló; Fernando Fernández Bañares; Lídia Argüello; Elena Peña; Angels Vilella; Sabino Riestra; Ramiro Carreño; Artemio Paya; Cristina Alenda; Rosa M Xicola; Brian J Doyle; Rodrigo Jover; Xavier Llor; Angel Carracedo; Antoni Castells; Sergi Castellví-Bel; Montserrat Andreu Journal: Gastroenterology Date: 2010-06-02 Impact factor: 22.682
Authors: Pandu P Nugroho; Siti Alyaa S Ghozali; Daniel D Buchanan; Mia I Pisano; Jeanette C Reece Journal: J Cancer Res Clin Oncol Date: 2022-10-17 Impact factor: 4.322
Authors: Pilar Mur; Elena Sánchez-Cuartielles; Susanna Aussó; Gemma Aiza; Rafael Valdés-Mas; Marta Pineda; Matilde Navarro; Joan Brunet; Miguel Urioste; Conxi Lázaro; Victor Moreno; Gabriel Capellá; Xose S Puente; Laura Valle Journal: Sci Rep Date: 2016-02-08 Impact factor: 4.379
Authors: Ana Macedo; Carlos Gómez; Miguel Ângelo Rebelo; Jesús Poza; Iva Gomes; Sandra Martins; Aarón Maturana-Candelas; Víctor Gutiérrez-de Pablo; Luis Durães; Patrícia Sousa; Manuel Figueruelo; María Rodríguez; Carmen Pita; Miguel Arenas; Luis Álvarez; Roberto Hornero; Alexandra M Lopes; Nádia Pinto Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472